ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients
The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consid...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-08, Vol.29 (8), p.1687-1700 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1700 |
|---|---|
| container_issue | 8 |
| container_start_page | 1687 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Hutchings, M. Ladetto, M. Buske, C. de Nully Brown, P. Ferreri, A.J.M. Pfreundschuh, M. Schmitz, N. Balari, A. Sureda van Imhoff, G. Walewski, J. |
| description | The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following ‘ultra-high-risk’ situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article. |
| doi_str_mv | 10.1093/annonc/mdy167 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2057443678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdy167</oup_id><els_id>S0923753419341067</els_id><sourcerecordid>2057443678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-698c3c1adea0440350d51eeb6b9dba0c5c09639668c8227a533a4f37d26376613</originalsourceid><addsrcrecordid>eNqFkM1O3DAURq2qqAy0y26rLLsJ4784cXdoNLRIg2YBXVaW49zMuCR2sBOk2fEY8Ho8CRllgFXV1b36dO53pYPQV4LPCJZsrp3zzszbakdE_gHNSCZkWmBOPqIZlpSlecb4MTqJ8S_GWEgqP6FjKiXlVIoZ-rO8vlonC-8iuDjE_VZDAGcg8S5pdWM3Trs-aXZtt_Wt_jFmTm-ghTH0dfL88Dg0fdDp1m62abDx9vnhKel0b0cgfkZHtW4ifDnMU_T7Ynmz-JWu1j8vF-er1HDC-lTIwjBDdAUac45ZhquMAJSilFWpsckMloJJIQpTUJrrjDHNa5ZXVLBcCMJO0feptwv-boDYq9ZGA02jHfghKoqznHMm8mJE0wk1wccYoFZdsK0OO0Ww2htVk1E1GR35b4fqoWyheqNfFb7_9kP33658QmF0cW8hqGjs3nVlA5heVd7-4_IFLh-XXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2057443678</pqid></control><display><type>article</type><title>ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Hutchings, M. ; Ladetto, M. ; Buske, C. ; de Nully Brown, P. ; Ferreri, A.J.M. ; Pfreundschuh, M. ; Schmitz, N. ; Balari, A. Sureda ; van Imhoff, G. ; Walewski, J.</creator><creatorcontrib>Hutchings, M. ; Ladetto, M. ; Buske, C. ; de Nully Brown, P. ; Ferreri, A.J.M. ; Pfreundschuh, M. ; Schmitz, N. ; Balari, A. Sureda ; van Imhoff, G. ; Walewski, J. ; ESMO Lymphoma Consensus Conference Panel Members</creatorcontrib><description>The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following ‘ultra-high-risk’ situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy167</identifier><identifier>PMID: 29924296</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>aggressive ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - standards ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - analysis ; Clinical Trials as Topic ; consensus ; Consensus Development Conferences as Topic ; Drug Resistance, Neoplasm ; Europe ; high-risk ; Humans ; lymphoma ; Lymphoma - diagnosis ; Lymphoma - pathology ; Lymphoma - therapy ; Medical Oncology - methods ; Medical Oncology - standards ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - therapy ; Practice Guidelines as Topic ; primary resistance ; Prognosis ; Radiotherapy, Adjuvant - methods ; Radiotherapy, Adjuvant - standards ; relapse ; Risk Factors ; Societies, Medical - standards ; Treatment Outcome</subject><ispartof>Annals of oncology, 2018-08, Vol.29 (8), p.1687-1700</ispartof><rights>2018 THE AUTHORS</rights><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-698c3c1adea0440350d51eeb6b9dba0c5c09639668c8227a533a4f37d26376613</citedby><cites>FETCH-LOGICAL-c413t-698c3c1adea0440350d51eeb6b9dba0c5c09639668c8227a533a4f37d26376613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27913,27914</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29924296$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hutchings, M.</creatorcontrib><creatorcontrib>Ladetto, M.</creatorcontrib><creatorcontrib>Buske, C.</creatorcontrib><creatorcontrib>de Nully Brown, P.</creatorcontrib><creatorcontrib>Ferreri, A.J.M.</creatorcontrib><creatorcontrib>Pfreundschuh, M.</creatorcontrib><creatorcontrib>Schmitz, N.</creatorcontrib><creatorcontrib>Balari, A. Sureda</creatorcontrib><creatorcontrib>van Imhoff, G.</creatorcontrib><creatorcontrib>Walewski, J.</creatorcontrib><creatorcontrib>ESMO Lymphoma Consensus Conference Panel Members</creatorcontrib><title>ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following ‘ultra-high-risk’ situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article.</description><subject>aggressive</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - standards</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Clinical Trials as Topic</subject><subject>consensus</subject><subject>Consensus Development Conferences as Topic</subject><subject>Drug Resistance, Neoplasm</subject><subject>Europe</subject><subject>high-risk</subject><subject>Humans</subject><subject>lymphoma</subject><subject>Lymphoma - diagnosis</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - therapy</subject><subject>Medical Oncology - methods</subject><subject>Medical Oncology - standards</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Practice Guidelines as Topic</subject><subject>primary resistance</subject><subject>Prognosis</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Radiotherapy, Adjuvant - standards</subject><subject>relapse</subject><subject>Risk Factors</subject><subject>Societies, Medical - standards</subject><subject>Treatment Outcome</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1O3DAURq2qqAy0y26rLLsJ4784cXdoNLRIg2YBXVaW49zMuCR2sBOk2fEY8Ho8CRllgFXV1b36dO53pYPQV4LPCJZsrp3zzszbakdE_gHNSCZkWmBOPqIZlpSlecb4MTqJ8S_GWEgqP6FjKiXlVIoZ-rO8vlonC-8iuDjE_VZDAGcg8S5pdWM3Trs-aXZtt_Wt_jFmTm-ghTH0dfL88Dg0fdDp1m62abDx9vnhKel0b0cgfkZHtW4ifDnMU_T7Ynmz-JWu1j8vF-er1HDC-lTIwjBDdAUac45ZhquMAJSilFWpsckMloJJIQpTUJrrjDHNa5ZXVLBcCMJO0feptwv-boDYq9ZGA02jHfghKoqznHMm8mJE0wk1wccYoFZdsK0OO0Ww2htVk1E1GR35b4fqoWyheqNfFb7_9kP33658QmF0cW8hqGjs3nVlA5heVd7-4_IFLh-XXw</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Hutchings, M.</creator><creator>Ladetto, M.</creator><creator>Buske, C.</creator><creator>de Nully Brown, P.</creator><creator>Ferreri, A.J.M.</creator><creator>Pfreundschuh, M.</creator><creator>Schmitz, N.</creator><creator>Balari, A. Sureda</creator><creator>van Imhoff, G.</creator><creator>Walewski, J.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201808</creationdate><title>ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients</title><author>Hutchings, M. ; Ladetto, M. ; Buske, C. ; de Nully Brown, P. ; Ferreri, A.J.M. ; Pfreundschuh, M. ; Schmitz, N. ; Balari, A. Sureda ; van Imhoff, G. ; Walewski, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-698c3c1adea0440350d51eeb6b9dba0c5c09639668c8227a533a4f37d26376613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>aggressive</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - standards</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Clinical Trials as Topic</topic><topic>consensus</topic><topic>Consensus Development Conferences as Topic</topic><topic>Drug Resistance, Neoplasm</topic><topic>Europe</topic><topic>high-risk</topic><topic>Humans</topic><topic>lymphoma</topic><topic>Lymphoma - diagnosis</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - therapy</topic><topic>Medical Oncology - methods</topic><topic>Medical Oncology - standards</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Practice Guidelines as Topic</topic><topic>primary resistance</topic><topic>Prognosis</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Radiotherapy, Adjuvant - standards</topic><topic>relapse</topic><topic>Risk Factors</topic><topic>Societies, Medical - standards</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hutchings, M.</creatorcontrib><creatorcontrib>Ladetto, M.</creatorcontrib><creatorcontrib>Buske, C.</creatorcontrib><creatorcontrib>de Nully Brown, P.</creatorcontrib><creatorcontrib>Ferreri, A.J.M.</creatorcontrib><creatorcontrib>Pfreundschuh, M.</creatorcontrib><creatorcontrib>Schmitz, N.</creatorcontrib><creatorcontrib>Balari, A. Sureda</creatorcontrib><creatorcontrib>van Imhoff, G.</creatorcontrib><creatorcontrib>Walewski, J.</creatorcontrib><creatorcontrib>ESMO Lymphoma Consensus Conference Panel Members</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hutchings, M.</au><au>Ladetto, M.</au><au>Buske, C.</au><au>de Nully Brown, P.</au><au>Ferreri, A.J.M.</au><au>Pfreundschuh, M.</au><au>Schmitz, N.</au><au>Balari, A. Sureda</au><au>van Imhoff, G.</au><au>Walewski, J.</au><aucorp>ESMO Lymphoma Consensus Conference Panel Members</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-08</date><risdate>2018</risdate><volume>29</volume><issue>8</issue><spage>1687</spage><epage>1700</epage><pages>1687-1700</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following ‘ultra-high-risk’ situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29924296</pmid><doi>10.1093/annonc/mdy167</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-08, Vol.29 (8), p.1687-1700 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2057443678 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | aggressive Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - standards Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - analysis Clinical Trials as Topic consensus Consensus Development Conferences as Topic Drug Resistance, Neoplasm Europe high-risk Humans lymphoma Lymphoma - diagnosis Lymphoma - pathology Lymphoma - therapy Medical Oncology - methods Medical Oncology - standards Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - therapy Practice Guidelines as Topic primary resistance Prognosis Radiotherapy, Adjuvant - methods Radiotherapy, Adjuvant - standards relapse Risk Factors Societies, Medical - standards Treatment Outcome |
| title | ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A35%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ESMO%20Consensus%20Conference%20on%20malignant%20lymphoma:%20management%20of%20%E2%80%98ultra-high-risk%E2%80%99%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Hutchings,%20M.&rft.aucorp=ESMO%20Lymphoma%20Consensus%20Conference%20Panel%20Members&rft.date=2018-08&rft.volume=29&rft.issue=8&rft.spage=1687&rft.epage=1700&rft.pages=1687-1700&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy167&rft_dat=%3Cproquest_cross%3E2057443678%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2057443678&rft_id=info:pmid/29924296&rft_oup_id=10.1093/annonc/mdy167&rft_els_id=S0923753419341067&rfr_iscdi=true |